NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting<
01 Jun 2022

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST
Galecto to Participate at Jefferies Healthcare Conference<
31 May 2022

Galecto to Participate at Jefferies Healthcare Conference

A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy<
31 May 2022

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting<
27 May 2022

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

These data show that AU-011, a first in class VDC, in combination with immune checkpoint inhibition is effective against both primary tumors and distant metastases in a preclinical model
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting<
26 May 2022

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified
Aura Biosciences to Participate in Upcoming Investor Conferences<
25 May 2022

Aura Biosciences to Participate in Upcoming Investor Conferences

Webcast of the Cowen fireside chat and Jefferies presentation will be available on Aura's “Investors & Media” page
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.<
23 May 2022

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022<
19 May 2022

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

Findings provide additional preclinical validation ahead of IND/CTA submission planned in Q3 2022
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results<
17 May 2022

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

• LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights<
12 May 2022

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

We continue to advance the AU-011 overall development program and look forward to several upcoming clinical milestones, in the second half of this year

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка